All News

Get a quick look at 13 of the many FDA-approved drugs in 2023 for conditions commonly seen in primary care.

Approval of the application would extend the current Arexvy indication for prevention of RSV in adults aged 60 years and older; a June 2024 PDUFA date is set.

Your daily dose of the clinical news you may have missed.

Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.

Results showed nearly one-third of hospitalizations for acute respiratory illness among children aged <5 years were associated with RSV.

Among women with PCOS, the risk for a suicide attempt was highest (by a factor of 9) among young adults aged 20 to 40 years, followed by adolescents.

Your daily dose of the clinical news you may have missed.

Influenza continues to rage in some parts of the US; try these 4 quick questions on vaccines you may or may not have on hand.

Updates in the Global Initiative for Obstructive Lung Disease report include using spirometry values in diagnosis and optimizing inhaled pharmacotherapy.

Your daily dose of the clinical news you may have missed.

Preventive health screenings have yet to rebound to pre-COVID-19 levels and Asian adults appear to have fallen behind more than other racial/ethnic groups, a new study finds.

Mean placebo-adjusted SBP change from baseline at 36 weeks was 8.6 mm Hg in adults with obesity, according to authors of the SURMOUNT-1 ABPM substudy.

Reported cases of chlamydia, syphilis, and gonorrhea in the US surpassed 2.5 million for the third time in 5 years, according to CDC.

Access to methadone and buprenorphine treatment may be easier and incentive to continue treatment could start at home, using telehealth, according to HHS.

Your daily dose of the clinical news you may have missed.

The combination SABA/ICS inhaler is the first of its kind and treats both acute bronchoconstriction and the inflammation that drives asthma and disease exacerbation.

The updated COVID-19 vaccines were approximately 54% effective against symptomatic SARS-CoV-2 infection, according to new data from the CDC.

In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.